Business
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy
About this update from Novocure Limited
[{"type":"text","content":" ROOT, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas.\n\n\nNovocure will present the results of its work to design arrays that will allow efficient and stable delivery of TTFields in mouse studies as well as research identifying the optimal positioning of its newly approved Head Flexible Electrodes (HFE) transducer arrays for infratentorial brain tumors. Novocure will also present a new subgroup analysis of patients from the xCures real-world data platform that assesses the results of treatment with TTFields in people with isocitrate dehydrogenase (IDH)-mutant glioblastoma.\n\n\nNovocure’s SNO 2024 Data Presentation Details\n\n\nOral Presentation (Abstract #TMOD-09): Newly designed Tumor Treating Fields (TTFields) arrays for the mouse head demonstrate efficacy for treatment of glioblastoma\nPresenting Author: Moshe Giladi, Novocure Ltd, Haifa, Israel\nDate/Time: Sunday, November 24; 8:30 –10:00 a.m. CST\n\n\nPoster INNV-14: Outcomes of patients with isocitrate dehydrogenase-mutant WHO Grade 4 astrocytoma treated with Tumor Treating Fields (TTFields) therapy: a real-world analysis\nPresenting Author: Jennifer M. Connelly, Department of Neurology, Medical College of Wisconsin, Milwaukee, WI\nDate/Time: Friday, November 22; 7:30 – 9:30 p.m. CST\n\n\nPoster INNV-11: Delivery of TTFields to the infratentorial brain using HFE arrays\nPresenting Author: Dheeraj Bhavanasi, Novocure\nDate/Time: Friday, November 22; 7:30 – 9:30 p.m. CST\n\n\nIn addition, more than 20 independent preclinical, translational, real-world evidence and clinical studies of TTFields will be presented at the 2024 SNO Annual Meeting. Abstracts can be viewed here: https://academic.oup.com/neuro-oncology/issue/26/Supplement_8\n\n\nNovocure will also host a sponsored symposium, From Evidence to Practice: Impact of TTFields Therapy on Patient Outcomes, which will be held Friday, November 22, 12:45 –1:45 p.m. CST in Meeting Room: 351 (Level 3 at the George R. Brown Convention Center).\n\n\nAbout Tumor Treating Fields\n\n\nTumor Treating Fields (TTFields) are electric fields that exert physical forces to kill cancer cells v...